Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts. (Q39167848)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28271871 AND SRC:MED&resulttype=core&format=json

5 April 2020

title

Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28271871 AND SRC:MED&resulttype=core&format=json

5 April 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28271871 AND SRC:MED&resulttype=core&format=json

5 April 2020

author name string

Winette T A van der Graaf

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28271871 AND SRC:MED&resulttype=core&format=json

5 April 2020

Daniel Orbach

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28271871 AND SRC:MED&resulttype=core&format=json

5 April 2020

Ian R Judson

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28271871 AND SRC:MED&resulttype=core&format=json

5 April 2020

publication date

2 March 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28271871 AND SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

5 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28271871 AND SRC:MED&resulttype=core&format=json

5 April 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28271871 AND SRC:MED&resulttype=core&format=json

5 April 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28271871 AND SRC:MED&resulttype=core&format=json

5 April 2020

page(s)

e166-e175

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28271871 AND SRC:MED&resulttype=core&format=json

Cancer in adolescents and young adults (15-29 years): a population-based study in the Netherlands 1989-2009.

5 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Epidemiology of childhood cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Survival of European adolescents and young adults diagnosed with cancer in 2000-07: population-based data from EUROCARE-5.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Participation of adolescents with cancer in clinical trials

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Children, adolescents, and young adults with leukemia: the empty half of the glass is growing

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

The Sooner the Better? How Symptom Interval Correlates With Outcome in Children and Adolescents With Solid Tumors: Regression Tree Analysis of the Findings of a Prospective Study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

The adolescence of young adult oncology

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Available, accessible, aware, appropriate, and acceptable: a strategy to improve participation of teenagers and young adults in cancer trials

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Starting an adolescent and young adult program: some success stories and some obstacles to overcome.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Teenagers and young adults with cancer in Europe: from national programmes to a European integrated coordinated project.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Age as an independent prognostic factor for survival of localised synovial sarcoma patients

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of P

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Current chemotherapeutic strategies for rhabdomyosarcoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: the road ahead.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Treatment for childhood rhabdomyosarcoma: the cost of cure.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

The IVADo regimen--a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Selecting multimodal therapy for rhabdomyosarcoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Rhabdomyosarcoma in adolescents

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Adult rhabdomyosarcoma: outcome following multimodality treatment

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Clinical pharmacology in the adolescent oncology patient

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Population pharmacokinetic investigation of actinomycin-D in children and young adults

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Cyclophosphamide pharmacokinetics in children

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Multidrug resistance proteins in rhabdomyosarcomas: comparison between children and adults

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Response to chemotherapy is not related to chromosome instability in synovial sarcoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children's Research Hospital

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Adult-Type Soft Tissue Sarcomas in Pediatric-Age Patients: Experience at the Istituto Nazionale Tumori in Milan

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

New concepts for the treatment of pediatric nonrhabdomyosarcoma soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Adult-type soft tissue sarcomas in paediatric age: A nomogram-based prognostic comparison with adult sarcoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Postoperative nomogram for 12-year sarcoma-specific death

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005).

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Adherence to consensus-based diagnosis and treatment guidelines in adult soft-tissue sarcoma patients: a French prospective population-based study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective TIssue CAncer NETwork (CONTICANET)

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Should soft tissue sarcomas be treated at high-volume centers? An analysis of 4205 patients

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Histology-Driven Therapy: The Importance of Diagnostic Accuracy in Guiding Systemic Therapy of Soft Tissue Tumors.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Ewing Sarcoma: Current Management and Future Approaches Through Collaboration

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Adolescent and young adult oncology. Clinical practice guidelines in oncology

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Monogenic and polygenic determinants of sarcoma risk: an international genetic study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

Collaboration and Networking

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(17)30099-2

7 January 2021

10.1016/S1470-2045(17)30099-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28271871 AND SRC:MED&resulttype=core&format=json

5 April 2020

1 reference